Dyne Therapeutics’ (DYN) “Buy” Rating Reaffirmed at HC Wainwright

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $46.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 265.66% from the company’s current price.

A number of other research analysts have also recently commented on DYN. Robert W. Baird initiated coverage on Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective on the stock. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, BMO Capital Markets assumed coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.85.

Dyne Therapeutics Price Performance

Shares of DYN opened at $12.58 on Monday. The stock’s 50-day moving average is $14.10 and its two-hundred day moving average is $24.66. The stock has a market cap of $1.42 billion, a PE ratio of -3.53 and a beta of 1.11. Dyne Therapeutics has a 12 month low of $11.18 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 6,237 shares of company stock valued at $77,760 over the last three months. 20.77% of the stock is owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its holdings in shares of Dyne Therapeutics by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock valued at $5,532,000 after purchasing an additional 698 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after purchasing an additional 721 shares during the last quarter. KBC Group NV grew its holdings in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the third quarter valued at approximately $34,000. Finally, Virtue Capital Management LLC grew its holdings in shares of Dyne Therapeutics by 4.4% during the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock valued at $834,000 after purchasing an additional 981 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.